King updates on pain pipeline at APS

The USA's King Pharmaceuticals presented results from its expanded pain management portfolio at the American Pain Society meeting in San Diego,  California.

Safety and efficacy data for Acurox (oxycodone/niacin) and scientific  data confirming validation of innovative measurement standards to  evaluate the likeability of opioid analgesics. King is developing  several novel opioid treatment options, including long-acting opioids  Embeda and Remoxy, and a short-acting agent, Acurox, each of which is  uniquely designed to deter misuse and abuse commonly associated with  currently-approved opioid analgesic products. New Drug Applications for  Acurox, Embeda and Remoxy are all currently under review by the Food and  Drug Administration.

"The variety and magnitude of data being presented at the American Pain  Society annual meeting demonstrates the commitment King has made to the  advance of pain management," said chief science officer Eric Carter. "We  expect to meet the need for effective opioid therapeutic options that  also have the potential to reduce the risk of inappropriate or  non-therapeutic use through our novel pain treatment product  candidates," he added.